dr. mirza on the engot-ov42-nsgo/avanova-triplet trial in recurrent ovarian cancer
Published 4 years ago • 106 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
0:56
dr. mirza on the implications of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
0:42
dr. zsiros discusses pembrolizumab triplet in recurrent ovarian cancer
-
0:49
dr. matulonis on cps as a potential biomarker in advanced recurrent ovarian cancer
-
0:53
dr. mirza on the impact of parp inhibitors in ovarian cancer
-
6:15
the gog-0213 trial in recurrent ovarian cancer
-
3:22
novel combination strategies in recurrent ovarian cancer
-
9:24
results from the engot-ov16/nova trial: efficacy and safety of niraparib in ovarian cancer